Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: Joe Smith who wrote (10780)	4/9/2002 10:34:21 AM
From: Bucky Katt	Respond to of 13094

BRLI got over $10 intraday.. I have traded it many times since those .66 shares, buying dips and selling peaks. I do have some original shares in a lt account though. Based on the micro-float, I think a BPRX type move is not out of the question. I did have to eat around $20k when the warrants expired...worthless But that is real small potatos compared to the gains.. Another bio dog, ARIA, has news today. I kinda figured they were leading it down the last few days. ARIAD Lead Cancer Drug Candidate Shrinks Tumors Through Tumor Starvation Late-Breaking News Presented at the American Association for Cancer Research Scientific Meeting CAMBRIDGE, Mass., Apr 9, 2002 (BW HealthWire) -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA chart, msgs) today reported, for the first time, that studies on its orally active drug candidate for cancer, AP23573, demonstrate potent tumor shrinkage through a novel mode of action -- dramatic metabolic arrest and inhibition of nutrient uptake in tumors leading to cancer-cell starvation. Animals with implanted tumors treated with AP23573 at low doses for only five days showed significant, sustained reduction in tumor volume even after termination of treatment: 46% reduction in AP23573-treated animals vs. 150% increase in untreated animals. Repeat treatment courses resulted in continued reduction in tumor volume. And XOMA has done a nice DCB since the big dump...But we knew that was in the works, right?